natgillin/translations-raw huggingface dataset:
In paragraph (2) of Αrticle 6a of Implementing Decision (EU) 2016/2008, the following point (e) is added:
pristojni organi zadevne države članice so uvedli letni program cepljenja proti vozličastemu dermatitisu na vseh območjih navedene države članice iz dela I Priloge I, ki je bil zaključen vsaj 28 dni pred datumom odpreme in ki je izpolnjeval pogoje iz Priloge II ter ga je odobrila Komisija, ter obvestili Komisijo in druge države članice o datumu začetka in zaključka tega programa cepljenja ter
the animals, irrespective of their individual vaccination status or vaccination in their holding of origin against lumpy skin disease, are moved from holdings situated in an area listed in Part I of Annex I to any destination situated within another area listed in Part I of Annex I of the same Member State provided that:
za primere premikov živali prek območja iz dela II Priloge I je bil vzpostavljen postopek usmerjanja v skladu s členom 12, pod nadzorom pristojnih organov v kraju izvora in tranzita ter namembnem kraju.“
the competent authorities of the Member State concerned have implemented an annual vaccination programme against lumpy skin disease in all the areas of that Member State listed in Part I of Annex I, which was completed at least 28 days prior to the date of dispatch, and which complied with the conditions laid down in Annex II and was approved by the Commission, and have informed the Commission and the other Member States of the commencement date and the completion date of this vaccination programme; and
Člen 2
in case the movement of the animals is carried out through an area listed in Part II of Annex I, a channelling procedure in accordance with Article 12 has been set up, under the control of the competent authorities of the places of origin, transit and destination.’
Ta sklep je naslovljen na države članice.
Article 2
V Bruslju, 16. maja 2018
Done at Brussels, 16 May 2018.
Član Komisije
For the Commission
UL L 395, 30.12.1989, str. 13.
Member of the Commission
UL L 224, 18.8.1990, str. 29.
OJ L 395, 30.12.1989, p. 13.
UL L 62, 15.3.1993, str. 69.
OJ L 224, 18.8.1990, p. 29.
UL L 18, 23.1.2003, str. 11.
OJ L 62, 15.3.1993, p. 69.
Izvedbeni sklep Komisije (EU) 2016/2008 z dne 15. novembra 2016 o nadzornih ukrepih za zdravje živali v zvezi z vozličastim dermatitisom v nekaterih državah članicah (UL L 310, 17.11.2016, str. 51).
OJ L 18, 23.1.2003, p. 11.
To poimenovanje ne posega v stališča o statusu ter je v skladu z RVSZN 1244 in mnenjem Meddržavnega sodišča o razglasitvi neodvisnosti Kosova.
Commission Implementing Decision (EU) 2016/2008 of 15 November 2016 concerning animal health control measures relating to lumpy skin disease in certain Member States (OJ L 310, 17.11.2016, p. 51).
Od prvega pojava vozličastega dermatitisa v celinski Evropi je Evropska agencija za varnost hrane (EFSA) o vozličastem dermatitisu pripravila nujno obvestilo, sprejeto 29. julija 2016, in dve poročili, odobreni 27. marca 2017 oziroma 29. januarja 2018.
Commission Implementing Decision (EU) 2018/745
Izvedbeni sklep Komisije (EU) 2018/745
(notified under document C(2018) 2817)
(notificirano pod dokumentarno številko C(2018) 2817)
Commission Implementing Decision 2014/709/EU lays down animal health control measures in relation to African swine fever in certain Member States, where there have been confirmed cases of that disease in domestic or feral pigs (the Member States concerned).
Izvedbeni sklep Komisije 2014/709/EU določa nadzorne ukrepe za zdravje živali v zvezi z afriško prašičjo kugo v nekaterih državah članicah, kjer so bili potrjeni primeri navedene bolezni pri domačih ali divjih prašičih (v nadaljnjem besedilu: zadevne države članice).
The Annex to that Implementing Decision demarcates and lists certain areas of the Member States concerned in Parts I to IV thereof, differentiated by the level of risk based on the epidemiological situation as regards that disease.
V delih I do IV Priloge k navedenemu izvedbenemu sklepu so nekatera območja zadevnih držav članic razmejena in navedena po različni stopnji tveganja zaradi epidemioloških razmer glede navedene bolezni.
The Annex to Implementing Decision 2014/709/EU has been amended several times to take account of changes in the epidemiological situation in the Union as regards African swine fever that needed to be reflected in that Annex.
Priloga k Izvedbenemu sklepu 2014/709/EU je bila večkrat spremenjena, da bi se upoštevale spremembe epidemioloških razmer glede afriške prašičje kuge v Uniji, ki jih je bilo treba vključiti v navedeno prilogo.
In March 2018, a case of African swine fever in wild boar was observed in central-eastern Poland (namely, in gmina Sniadowo, gmina Latowicz and gmina Zambrow) in areas of Poland listed in Part I of the Annex to Implementing Decision 2014/709/EU.
Marca 2018 je bil ugotovljen primer afriške prašičje kuge pri divjih prašičih na osrednjevzhodnem delu Poljske (tj. v občini Sniadowo, občini Latowicz in občini Zambrow) na območjih na Poljskem, ki so navedena v delu I Priloge k Izvedbenemu sklepu 2014/709/EU.
Also, other cases were observed in the south-eastern part of Poland (namely, in gmina Urszulin and gmina Zmudz) in areas of Poland listed in Part II of the Annex to Implementing Decision 2014/709/EU.
Prav tako so bili drugi primeri ugotovljeni na jugovzhodnem delu Poljske (tj. v občini Urszulin in občini Zmudz) na območjih na Poljskem, ki so navedena v delu II Priloge k Izvedbenemu sklepu 2014/709/EU.
These cases constitute an increased level of risk that should be reflected in that Annex.
Ti primeri pomenijo povišanje stopnje tveganja, ki bi moralo biti odraženo v navedeni prilogi.
Also in March 2018, a case of African swine fever in wild boar was observed in south-eastern Latvia (namely, in the Saldus region) at the boundary between an area listed in Part I and an area listed in Part II of the Annex to Implementing Decision 2014/709/EU.
Marca 2018 je bil ugotovljen tudi primer afriške prašičje kuge pri divjih prašičih na jugovzhodnem delu Latvije (tj. v regiji Saldus) na meji med območjema, ki sta navedeni v delu I oziroma v delu II Priloge k Izvedbenemu sklepu 2014/709/EU.
This case constitutes an increased level of risk that should be reflected in that Annex.
Ta primer pomeni povišanje stopnje tveganja, ki bi moralo biti odraženo v navedeni prilogi.
In order to take account of recent developments in the epidemiological evolution of African swine fever in the Union, and in order to combat the risks associated with the spread of that disease in a proactive manner, new high risk areas of a sufficient size should be demarcated for Poland and Latvia and included in the lists in Parts I and II of the Annex to Implementing Decision 2014/709/EU.
Da bi se upoštevale nedavne spremembe pri epidemiološkem razvoju afriške prašičje kuge v Uniji in proaktivno obvladovala tveganja, povezana s širjenjem navedene bolezni, bi bilo treba razmejiti dovolj velika nova območja z visokim tveganjem na Poljskem in v Latviji ter jih vključiti na seznama v delih I in II Priloge k Izvedbenemu sklepu 2014/709/EU.
That Annex should therefore be amended accordingly.
Navedeno prilogo bi bilo zato treba ustrezno spremeniti.
Done at Brussels, 16 May 2018.
V Bruslju, 16. maja 2018
EFSA Journal 2015;13(7):4163 [92 pp.]; EFSA Journal 2017;15(3):4732 [73 pp.]; and EFSA Journal 2017;15(11): 5068 [30 pp.].
EFSA Journal 2015;13(7):4163 [92 str.]; EFSA Journal 2017;15(3):4732 [73 str.] in EFSA Journal 2017;15(11): 5068 [30 str.].
Lithuania
Naslednja območja v Litvi:
The following areas in Lithuania:
Poljska
Poland
DEL II
The following areas in Poland:
DEL III
PART II
Italija
Council Implementing Decision (EU) 2018/747
Izvedbeni sklep Sveta (EU) 2018/747
on subjecting the new psychoactive substance N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA) to control measures
o uvedbi nadzornih ukrepov za novo psihoaktivno snov N-(1-amino-3,3-dimetil-1-oksobutan-2-il)-1-(cikloheksilmetil)-1H-indazol-3-karboksamid (ADB-CHMINACA)
Having regard to Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new psychoactive substances, and in particular Article 8(3) thereof,
ob upoštevanju Sklepa Sveta 2005/387/PNZ z dne 10. maja 2005 o izmenjavi podatkov, oceni tveganja in nadzoru nad novimi psihoaktivnimi snovmi ter zlasti člena 8(3) Sklepa,
In accordance with Article 6 of Decision 2005/387/JHA, a risk assessment report on the new psychoactive substance N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (‘ADB-CHMINACA’) was drawn up by a special session of the extended Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction and was submitted to the Commission and to the Council on 14 November 2017.
V skladu s členom 6 Sklepa 2005/387/PNZ je bilo poročilo o oceni tveganja glede nove psihoaktivne snovi N-(1-amino-3,3-dimetil-1-oksobutan-2-il)-1-(cikloheksilmetil)-1H-indazol-3-karboksamid (v nadaljnjem besedilu: ADB-CHMINACA) pripravljeno na posebnem sestanku razširjenega znanstvenega odbora Evropskega centra za spremljanje drog in zasvojenosti z drogami ter je bilo 14. novembra 2017 predloženo Komisiji in Svetu.
ADB-CHMINACA is a synthetic cannabinoid.
ADB-CHMINACA je sintetični kanabinoid.
It has similar effects to those of THC, which is responsible for the major psychoactive effects of cannabis, but ADB-CHMINACA has additional life-threatening toxicity.
Ima podobne učinke kot THC, ki je odgovoren za glavne psihoaktivne učinke kanabisa, vendar ima ADB-CHMINACA dodatno smrtno strupenost.
The high potency of ADB-CHMINACA on the one hand, and the fact that it can account for a large or unknown variable proportion of smoking mixtures on the other, means that it constitutes a significant poisoning risk.
Zaradi velike jakosti ADB-CHMINACA na eni strani ter dejstva, da lahko predstavlja veliko ali neznano spremenljivo vsebnost v mešanicah za kajenje na drugi strani, predstavlja veliko tveganje zastrupitve.
ADB-CHMINACA has been available in the Union since at least August 2014 and has been detected in 17 Member States.
ADB-CHMINACA je v Uniji na voljo vsaj od avgusta 2014 in je bil odkrit v 17 državah članicah.
Due to the nature of ADB-CHMINACA, cases of detection are likely to be underreported since ADB-CHMINACA is not routinely screened for.
Zaradi narave ADB-CHMINACA se verjetno ni poročalo o vseh odkritih primerih, ker se ADB-CHMINACA ne preverja rutinsko.
In most cases, ADB-CHMINACA was seized as herbal or plant material and in powder form, but it has also been seized, though to a lesser extent, in other physical forms, for example in blotter form.
Najpogosteje je bil ADB-CHMINACA zasežen v obliki rastlinske snovi in praška, v manjšem obsegu pa tudi v drugih fizičnih oblikah, na primer v obliki pivnika.
More than 630 seizures have been made within the Union.
V Uniji je bilo izvedenih več kot 630 zasegov.
Three Member States have reported 13 deaths associated with ADB-CHMINACA.
Tri države članice so poročale o 13 smrtnih primerih, povezanih z ADB-CHMINACA.
In the case of at least nine deaths, ADB-CHMINACA was either the cause of death or was likely to have contributed to the death.
V vsaj devetih smrtnih primerih je bil ADB-CHMINACA bodisi vzrok smrti bodisi je verjetno prispeval k smrtnemu izidu.
In addition, one Member State reported three acute non-fatal intoxications associated with ADB-CHMINACA.
Poleg tega je ena država članica poročala o treh akutnih zastrupitvah brez smrtnega izida, povezanih z ADB-CHMINACA.
Due to the nature of ADB-CHMINACA, both non-fatal intoxications and deaths caused by ADB-CHMINACA are likely to be underdetected and underreported.
Zaradi narave ADB-CHMINACA verjetno niso bili odkriti in sporočeni vsi primeri zastrupitev zaradi ADB-CHMINACA brez smrtnega izida in smrtni primeri.
There is no information on the involvement of organised crime in the manufacture, distribution, trafficking and supply of ADB-CHMINACA within the Union.
Informacij o morebitni vpletenosti organiziranega kriminala v proizvodnjo, distribucijo, trgovino in dobavo ADB-CHMINACA znotraj Unije ni.
The available data suggest that ADB-CHMINACA is produced by chemical companies in China.
Iz razpoložljivih podatkov je razvidno, da ADB-CHMINACA proizvajajo kemična podjetja na Kitajskem.
ADB-CHMINACA is typically sold in small and wholesale amounts in head shops, branded as a so-called legal-high, as smoking mixtures or as powder, as well as on the internet, branded as a so-called legal replacement for cannabis.
ADB-CHMINACA se običajno prodaja v majhnih količinah in količinah za prodajo na debelo v trgovinah s pripomočki za uporabo drog kot tako imenovano dovoljeno omamno sredstvo, v obliki mešanic za kajenje ali kot prašek, ter na spletu kot tako imenovani zakonit nadomestek za kanabis.
It is also likely to be sold directly on the illicit drug market.
Prav tako je verjetno, da se prodaja neposredno na trgu prepovedanih drog.
As the packaging of such products rarely state the ingredients, most users are unaware that they are using ADB-CHMINACA, or even synthetic cannabinoids in general.
Ker so na embalaži takih proizvodov sestavine redko navedene, se večina uporabnikov ne zaveda, da uporabljajo ADB-CHMINACA ali sintetične kanabinoide na splošno.
ADB-CHMINACA has no recognised human or veterinary medical use in the Union nor, it appears, elsewhere.
ADB-CHMINACA nima niti v Uniji niti, kot kaže, nikjer drugje nobene priznane uporabe v humani ali veterinarski medicini.
There are no indications that ADB-CHMINACA can be used for any other purpose aside from as an analytical reference standard and in scientific research.
Ni znakov, da bi se ADB-CHMINACA lahko uporabljal za druge namene, z izjemo uporabe kot analitični referenčni standard in v znanstvenih raziskavah.
The risk assessment report reveals that many of the questions related to ADB-CHMINACA that are posed by the lack of data on the risks to individual health, risks to public health, and social risks, could be answered through further research.
V poročilu o oceni tveganja je navedeno, da bi odgovore na številna vprašanja v zvezi z ADB-CHMINACA, ki se zastavljajo zaradi pomanjkanja podatkov o tveganjih za zdravje posameznikov, tveganjih za javno zdravje in socialnih tveganjih, lahko prinesle nadaljnje raziskave.
However, the available evidence and information on the health and social risks that the substance poses provides sufficient grounds for subjecting ADB-CHMINACA to control measures across the Union.
Vendar so razpoložljivi dokazi in informacije o zdravstvenih in socialnih tveganjih, ki jih predstavlja ta snov, zadostna podlaga za uvedbo nadzornih ukrepov za ADB-CHMINACA po vsej Uniji.
ADB-CHMINACA is not currently under assessment by the United Nations system.
Sklep 2005/387/PNZ Svetu podeljuje izvedbena pooblastila, da bi se bilo mogoče na ravni Unije z uvedbo nadzornih ukrepov po vsej Uniji za nove psihoaktivne snovi hitro in strokovno odzvati na njihov pojav, ki ga države članice ugotovijo in o njem poročajo.
Given that 13 Member States control ADB-CHMINACA under national drug control legislation and four Member States control ADB-CHMINACA under other legislation, subjecting ADB-CHMINACA to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and would help protect from the risks that its availability and use poses.
Ker so pogoji za izvrševanje teh izvedbenih pooblastil izpolnjeni in postopki upoštevani, bi bilo treba sprejeti izvedbeni sklep za uvedbo nadzornih ukrepov za ADB-CHMINACA po vsej Uniji.
Decision 2005/387/JHA confers implementing powers upon the Council with a view to giving a quick and expertise-based response at Union level to the emergence of new psychoactive substances detected and reported by the Member States, by subjecting those substances to control measures across the Union.
Sklep 2005/387/PNZ je za Dansko zavezujoč, zato Danska sodeluje pri sprejetju in uporabi tega sklepa, s katerim se izvaja Sklep 2005/387/PNZ.
As the conditions and procedure for triggering the exercise of such implementing powers have been met, an implementing decision should be adopted in order to subject ADB-CHMINACA to control measures across the Union.
Sklep 2005/387/PNZ je za Irsko zavezujoč, zato Irska sodeluje pri sprejetju in uporabi tega sklepa, s katerim se izvaja Sklep 2005/387/PNZ..
Denmark is bound by Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision, which implements Decision 2005/387/JHA.
Sklep 2005/387/PNZ za Združeno kraljestvo ni zavezujoč, zato Združeno kraljestvo ne sodeluje pri sprejetju in uporabi tega sklepa in zato zanj ni zavezujoč ter se v njem ne uporablja –
Ireland is bound by Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision, which implements Decision 2005/387/JHA.
SPREJEL NASLEDNJI SKLEP:
The United Kingdom is not bound by Decision 2005/387/JHA and is therefore not taking part in the adoption and application of this Decision and is not bound by it or subject to its application,
Člen 1
HAS ADOPTED THIS DECISION:
Za novo psihoaktivno snov N-(1-amino-3,3-dimetil-1-oksobutan-2-il)-1-(cikloheksilmetil)-1H-indazol-3-karboksamid (ADB-CHMINACA) se uvedejo nadzorni ukrepi po vsej Uniji.
The new psychoactive substance N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (‘ADB-CHMINACA’) shall be subjected to control measures across the Union.
Države članice do 23. maja 2019 sprejmejo potrebne ukrepe v skladu s svojim nacionalnim pravom, da za ADB-CHMINACA uvedejo nadzorne ukrepe in kazenske sankcije, kot jih določa njihova zakonodaja v skladu z njihovimi obveznostmi iz Konvencije Združenih narodov o psihotropnih substancah iz leta 1971.
By 23 May 2019, Member States shall take the necessary measures, in accordance with their national law, to subject ADB-CHMINACA to control measures and criminal penalties, as provided for under their legislation, in compliance with their obligations under the 1971 United Nations Convention on Psychotropic Substances.
Ta sklep začne veljati dan po objavi v Uradnem listu Evropske unije.
This Decision shall enter into force on the date following that of its publication in the Official Journal of the European Union.
V Bruslju, 14. maja 2018
For the Council
UL L 127, 20.5.2005, str. 32.
E. Zaharieva
ADB-CHMINACA ni na seznamu za nadzor na podlagi Enotne konvencije Združenih narodov o mamilih iz leta 1961 ali Konvencije Združenih narodov o psihotropnih substancah iz leta 1971.
OJ L 127, 20.5.2005, p. 32.
ADB-CHMINACA trenutno ni v postopku ocenjevanja v okviru sistema Združenih narodov.
Council Implementing Decision (EU) 2018/748
Izvedbeni sklep Sveta (EU) 2018/748
on subjecting the new psychoactive substance 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) to control measures
o uvedbi nadzornih ukrepov za novo psihoaktivno snov 1-(4-cianobutil)-N-(2-fenilpropan-2-il)-1H-indazol-3-karboksamid (CUMYL-4CN-BINACA)
Having regard to Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new psychoactive substances, and in particular Article 8(3) thereof,
ob upoštevanju Sklepa Sveta 2005/387/PNZ z dne 10. maja 2005 o izmenjavi podatkov, oceni tveganja in nadzoru nad novimi psihoaktivnimi snovmi ter zlasti člena 8(3) Sklepa,
In accordance with Article 6 of Decision 2005/387/JHA, a risk assessment report on the new psychoactive substance 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (‘CUMYL-4CN-BINACA’) was drawn up by a special session of the extended Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction and was submitted to the Commission and to the Council on 14 November 2017.
V skladu s členom 6 Sklepa 2005/387/PNZ je bilo poročilo o oceni tveganja glede nove psihoaktivne snovi 1-(4-cianobutil)-N-(2-fenilpropan-2-il)-1H-indazol-3-karboksamid (v nadaljnjem besedilu: CUMYL-4CN-BINACA) pripravljeno na posebnem sestanku razširjenega znanstvenega odbora Evropskega centra za spremljanje drog in zasvojenosti z drogami ter je bilo 14. novembra 2017 predloženo Komisiji in Svetu.
CUMYL-4CN-BINACA is a synthetic cannabinoid.
CUMYL-4CN-BINACA je sintetični kanabinoid.
It has similar effects to those of THC, which is responsible for the major psychoactive effects of cannabis, but CUMYL-4CN-BINACA has additional life-threatening toxicity.
Ima podobne učinke kot THC, ki je odgovoren za glavne psihoaktivne učinke kanabisa, vendar ima CUMYL-4CN-BINACA dodatno smrtno strupenost.
The high potency of CUMYL-4CN-BINACA on the one hand, and the fact that it can account for a large or unknown variable proportion of smoking mixtures on the other, means that it constitutes a significant poisoning risk.
Zaradi velike jakosti CUMYL-4CN-BINACA na eni strani ter dejstva, da lahko predstavlja veliko ali neznano spremenljivo vsebnost v mešanicah za kajenje na drugi strani, predstavlja veliko tveganje zastrupitve.
CUMYL-4CN-BINACA has been available in the Union since at least October 2015 and has been detected in 11 Member States.
CUMYL-4CN-BINACA je v Uniji na voljo vsaj od oktobra 2015 in je bil odkrit v 11 državah članicah.
Due to the nature of CUMYL-4CN-BINACA, cases of detection are likely to be underreported since CUMYL-4CN-BINACA is not routinely screened for.
Zaradi narave CUMYL-4CN-BINACA se verjetno ni poročalo o vseh odkritih primerih, ker se CUMYL-4CN-BINACA ne preverja rutinsko.
In most cases, CUMYL-4CN-BINACA was seized as powder or herbal material, but it has also been seized, though to a lesser extent, in other physical forms, for example in blotter form.
Najpogosteje je bil CUMYL-4CN-BINACA zasežen v obliki praška ali rastlinske snovi, v manjšem obsegu pa je bil zasežen tudi v drugih fizičnih oblikah, na primer v obliki pivnika.
More than 270 seizures have been made within the Union.
V Uniji je bilo izvedenih več kot 270 zasegov.
11 deaths associated with CUMYL-4CN-BINACA have been reported by two Member States.
Dve državi članici sta v zvezi s CUMYL-4CN-BINACA poročali o 11 smrtnih primerih.
In the case of at least five of those deaths CUMYL-4CN-BINACA was the cause of death or was likely to have contributed to the death.
V vsaj petih od teh smrtnih primerov je bil CUMYL-4CN-BINACA bodisi vzrok smrti bodisi je verjetno prispeval k smrtnemu izidu.
In addition, five acute non-fatal intoxications associated with CUMYL-4CN-BINACA were reported by two Member States.
Poleg tega sta dve državi članici poročali o petih akutnih zastrupitvah brez smrtnega izida, povezanih s CUMYL-4CN-BINACA.
Due to the nature of CUMYL-4CN-BINACA, both non-fatal intoxications and deaths caused by CUMYL-4CN-BINACA are likely to be underdetected and underreported.
Zaradi narave CUMYL-4CN-BINACA verjetno niso bili odkriti in sporočeni vsi primeri zastrupitev zaradi CUMYL-4CN-BINACA brez smrtnega izida in smrtni primeri.
There is no information on the involvement of organised crime in the manufacture, distribution, trafficking and supply of CUMYL-4CN-BINACA within the Union.
Informacij o morebitni vpletenosti organiziranega kriminala v proizvodnjo, distribucijo, trgovino in dobavo CUMYL-4CN-BINACA znotraj Unije ni.
The available data suggest that CUMYL-4CN-BINACA is produced by chemical companies in China.
Iz razpoložljivih podatkov je razvidno, da CUMYL-4CN-BINACA proizvajajo kemična podjetja na Kitajskem.
CUMYL-4CN-BINACA is typically sold in small and wholesale amounts in head shops, branded as a so-called legal-high, as smoking mixtures or as powder, as well as on the internet, branded as a so-called legal replacement for cannabis.
CUMYL-4CN-BINACA se običajno prodaja v majhnih količinah in količinah za prodajo na debelo v trgovinah s pripomočki za uporabo drog kot tako imenovano dovoljeno omamno sredstvo, v obliki mešanic za kajenje ali kot prašek, ter na spletu kot tako imenovani zakonit nadomestek za kanabis.